A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET
inhibitor crizotinib in patients with RAS mutant advanced
colorectal cancer (MErCuRIC)

ENPřihlásit se Přihlásit se (EduID)

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with ...

Přehled o publikaci

J 2025

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

AROLDI, Francesca; Elena ELEZ; Thierry ANDRE; Geraldine PERKINS; Hans PRENEN et. al.

Základní údaje

Originální název

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

Autoři

Vydání

BMC Cancer, London, UK, BioMed Central, 2025, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Přírodovědecká fakulta – Masarykova univerzita – Repozitář

DOI

http://dx.doi.org/10.1186/s12885-025-14068-1

UT WoS

001464766800010

EID Scopus

2-s2.0-105003323271

Klíčová slova anglicky

RAS mutant; Colorectal cancer; Phase I; Binimetinib; Crizotinib; Pharmacokinetics; Pharmacodynamics; MET biomarker; CtDNA

Návaznosti

602901, interní kód Repo.

Změněno: 18. 7. 2025 00:50, RNDr. Daniel Jakubík

Anotace

V originále

gt; 180 and MET ISH + 3) was observed in 7 patients (24.1%), with MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baseline RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baseline KRASMT allele frequency. Conclusions Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.EudraCT-Number: 2014-000463 - 40 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).

Přiložené soubory

https://is.muni.cz/publication/2507624/2507624.pdf

Citovat

AROLDI, Francesca; Elena ELEZ; Thierry ANDRE; Geraldine PERKINS; Hans PRENEN; Vlad POPOVICI; Peter GALLAGHER; Jennifer HOULDEN; Linda COLLINS; Corran ROBERTS; Christian ROLFO; Federica DI NICOLANTONIO; Margaret GRAYSON; Ruth BOYD; Karolien BETTENS; Jurgen DELFAVERO; Victoria COYLE; Mark LAWLER; Hajrah KHAWAJA; Pierre LAURENT-PUIG; Manuel SALTO-TELLEZ; Tim S. MAUGHAN; Josep TABERNERO; Richard ADAMS; Robert JONES; Bryan T. HENNESSY; Alberto BARDELLI; Marc PEETERS; Mark R. MIDDLETON; Richard H. WILSON a Sandra VAN SCHAEYBROECK. A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). BMC Cancer. London, UK: BioMed Central, 2025, roč. 25, č. 1, s. 1-15. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-025-14068-1.

@article{77544,
   author = {Aroldi, Francesca and Elez, Elena and Andre, Thierry and Perkins, Geraldine and Prenen, Hans and Popovici, Vlad and Gallagher, Peter and Houlden, Jennifer and Collins, Linda and Roberts, Corran and Rolfo, Christian and Di Nicolantonio, Federica and Grayson, Margaret and Boyd, Ruth and Bettens, Karolien and Delfavero, Jurgen and Coyle, Victoria and Lawler, Mark and Khawaja, Hajrah and LaurentandPuig, Pierre and SaltoandTellez, Manuel and Maughan, Tim S. and Tabernero, Josep and Adams, Richard and Jones, Robert and Hennessy, Bryan T. and Bardelli, Alberto and Peeters, Marc and Middleton, Mark R. and Wilson, Richard H. and Van Schaeybroeck, Sandra},
   article_location = {London, UK},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s12885-025-14068-1},
   keywords = {RAS mutant; Colorectal cancer; Phase I; Binimetinib; Crizotinib; Pharmacokinetics; Pharmacodynamics; MET biomarker; CtDNA},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14068-1},
   volume = {25},
   year = {2025}
}

TY  - JOUR
ID  - 77544
AU  - Aroldi, Francesca - Elez, Elena - Andre, Thierry - Perkins, Geraldine - Prenen, Hans - Popovici, Vlad - Gallagher, Peter - Houlden, Jennifer - Collins, Linda - Roberts, Corran - Rolfo, Christian - Di Nicolantonio, Federica - Grayson, Margaret - Boyd, Ruth - Bettens, Karolien - Delfavero, Jurgen - Coyle, Victoria - Lawler, Mark - Khawaja, Hajrah - Laurent-Puig, Pierre - Salto-Tellez, Manuel - Maughan, Tim S. - Tabernero, Josep - Adams, Richard - Jones, Robert - Hennessy, Bryan T. - Bardelli, Alberto - Peeters, Marc - Middleton, Mark R. - Wilson, Richard H. - Van Schaeybroeck, Sandra
PY  - 2025
TI  - A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
JF  - BMC Cancer
VL  - 25
IS  - 1
SP  - 1-15
EP  - 1-15
PB  - BioMed Central
SN  - 1471-2407
KW  - RAS mutant
KW  - Colorectal cancer
KW  - Phase I
KW  - Binimetinib
KW  - Crizotinib
KW  - Pharmacokinetics
KW  - Pharmacodynamics
KW  - MET biomarker
KW  - CtDNA
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14068-1
N2  - gt; 180 and MET ISH + 3) was observed in 7 patients (24.1%), with MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baseline RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baseline KRASMT allele frequency. Conclusions Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.EudraCT-Number: 2014-000463 - 40 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).
ER  -

AROLDI, Francesca; Elena ELEZ; Thierry ANDRE; Geraldine PERKINS; Hans PRENEN; Vlad POPOVICI; Peter GALLAGHER; Jennifer HOULDEN; Linda COLLINS; Corran ROBERTS; Christian ROLFO; Federica DI NICOLANTONIO; Margaret GRAYSON; Ruth BOYD; Karolien BETTENS; Jurgen DELFAVERO; Victoria COYLE; Mark LAWLER; Hajrah KHAWAJA; Pierre LAURENT-PUIG; Manuel SALTO-TELLEZ; Tim S. MAUGHAN; Josep TABERNERO; Richard ADAMS; Robert JONES; Bryan T. HENNESSY; Alberto BARDELLI; Marc PEETERS; Mark R. MIDDLETON; Richard H. WILSON a Sandra VAN SCHAEYBROECK. A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). \textit{BMC Cancer}. London, UK: BioMed Central, 2025, roč.~25, č.~1, s.~1-15. ISSN~1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-025-14068-1.